BioSpace News Archive

Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2020 after the market close on Thursday, May 7, 2020. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a pre-emptive plan to support the U.S. aesthetic neurotoxin market in light of the COVID-19 pandemic. “We are in unprecedented times. As a result of COVID-19, social norms have evolved and the reliance on technology has accelerated. Since launch, the combination of our experienced sal

Vizient Inc. applauds the decision announced today by the Food and Drug Administration (FDA) to allow hospital pharmacies to begin compounding a range of pharmaceuticals used for COVID-19 patients, including many medications necessary for those on ventilators.

Vent Multiplexor, LLC (www.ventmultiplexor.com) and Yale New Haven Hospital announced today that the Food and Drug Administration has granted Emergency Use Authorization for the Vent Multiplexor, a life-saving emergency rescue device developed by Vent Multiplexor LLC in collaboration with Yale New Haven Hospita

Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) is pleased to announce the appointment of Donald McInnes as chief executive officer of the Company, filing the vacancy left by the resignation of Eric Willis.

A study led by UnitedHealth Group (NYSE: UNH) Research & Development and The Everett Clinic, part of Optum, revealed alternative swab materials and commonly available saline are effective for COVID-19 testing, providing more options for sample collection.

Cutera, Inc. (NASDAQ: CUTR) (“Cutera”), a provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced the pricing of an underwritten public offering of 2,385,000 shares of its common stock at a public offering price of $10.50 per share.

Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix”), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it ha

Alphamab Oncology announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly-owned subsidiary of the Company, received Safe to Proceed Letter from the US Food & Drug Administration for its recombinant humanized PD-L1/CTLA-4 bispecific antibody KN046, to initiate Phase II clinical trial in anti-PD-1 refractory or relapsed Non-Small-Cell Lung Cancer.

The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced